148134-23-0

Basic information

• Product Name: 3-Thiophenecarboxaldehyde,oxime,(E)-(9CI)
• Synonyms: 3-Thiophenecarboxaldehyde,oxime,(E)-(9CI);(NE)-N-(thiophen-3-ylmethylidene)hydroxylamine
• CAS NO: 148134-23-0
• Molecular Formula: C₅H₅NOS
• Molecular Weight: 127.16
• Product Categories: OXIME
• Mol File: 148134-23-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Thiophenecarboxaldehyde,oxime,(E)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Thiophenecarboxaldehyde,oxime,(E)-(9CI)(148134-23-0)
• EPA Substance Registry System: 3-Thiophenecarboxaldehyde,oxime,(E)-(9CI)(148134-23-0)

Safety Data

• Hazardous Substances Data: 148134-23-0(Hazardous Substances Data)

Upstream product

• 498-62-4 3-thiophene carboxaldehyde 
• 3199-44-8 3-formylthiophene diethyl acetal 

Downstream Products

• 1641-09-4 3-thiophenecarbonitrile 
• 27757-86-4 (3-thienylmethyl)amine 
• 101445-57-2 phenyl-[3]thienyl ketone-(2,4-dinitro-phenylhydrazone) 
• 6453-99-2 3-benzoylthiophene 

Relevant articles and documents

Systematic structure-activity relationship (SAR) exploration of diarylmethane backbone and discovery of a highly potent novel uric acid transporter 1 (URAT1) inhibitor

In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a-1x and 1ha-1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200-and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.

Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists

The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

Selective synthesis of E and Z isomers of oximes

The highly stereoselective conversion of aldehydes and ketones to their corresponding oximes with hydroxylamin hydrochloride are catalyzed by CuSO4 and K2CO3. This method occurs under mild reaction conditions with high yields.